One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
COMPARE LAAO: Rationale and design of the randomized controlled trial “COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy�
Marina Huijboom, MD a,b , Moniek Maarse, MD a,b,1 , Errol Aarnink, MD a,b,1 , Vincent van Dijk, MD, PhD a , Martin Swaans, MD, PhD a , Jeroen van der Heijden, MD, PhD c , Sander IJsselmuiden, MD, PhD d , Richard Folkeringa, MD, PhD e , Yuri Blaauw, MD, PhD f , Arif Elvan, MD, PhD g , Jeroen Stevenhagen, MD, PhD h , George Vlachojannis, MD, PhD i , Pepijn van der Voort, MD, PhD j , Sjoerd Westra, MD k , Marisevi Chaldoupi, MD, PhD l , Muchtiar Khan, MD m , Joris de Groot, MD, PhD b , Frank van der Kley, MD n , Nicolas van Mieghem, MD, PhD o , Ewoud van Dijk, MD, PhD p , Marcel Dijkgraaf, MD, PhD q , Jan Tijssen, MD, PhD r , and Lucas Boersma, MD, PhD a,b Nieuwegein, The Netherlands; Nieuwegein, The Netherlands
doi : 10.1016/j.ahj.2022.05.001
Volume 250, August 2022, Pages 45-56
Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and meta-analysis
Paul M. Hendriks, MD a,b , Liza D. van de Groep, MD c , Kevin M. Veen, MD, PhD d , Mitch C.J. van Thor, MD, PhD c , Sabrina Meertens, MSc e , Eric Boersma, MSc, PhD, FESC a,f , Karin A. Boomars, MD, PhD b , Marco C. Post, MD, PhD c,g , and Annemien E. van den Bosch, MD, PhD a The Netherlands
doi : 10.1016/j.ahj.2022.05.006
Volume 250, August 2022, Pages 34-44
Multiple biomarkers have been investigated in the risk stratification of patients with pulmonary arterial hypertension (PAH). This systematic review and meta-analysis is the first to investigate the prognostic value of (NT-pro)BNP in patients with PAH.
Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta-analysis
Aakash Garg, MD a , Amit Rout, MD b , Serdar Farhan, MD c , Sergio Waxman, MD d , Gennaro Giustino, MD b , Raj Tayal, MD e , Jinette Dawn Abbott, MD a , Kurt Huber, MD f , Dominick J. Angiolillo, MD, PhD g , and Sunil V. Rao, MD h Rhode Island, USA; Kentucky, USA; New York, USA; New Jersey, USA; Vienna, Austria; Florida, USA; NC, USA;
doi : 10.1016/j.ahj.2022.04.004
Volume 250, August 2022, Pages 1-10
Optimal dual antiplatelet therapy (DAPT) duration in patients at high bleeding risk (HBR) is not fully defined. We aimed to compare the safety and effectiveness of short-term DAPT (S-DAPT) with longer duration DAPT (L-DAPT) after percutaneous coronary intervention (PCI) with drug eluting stents (DES) in patients at HBR.
Comparison of severe maternal morbidity in pregnancy by modified World Health Organization Classification of maternal cardiovascular risk
Anna E. Denoble, MD, MSCR a , Sarah A. Goldstein, MD b , Lauren E. Wein, BA c , Chad A. Grotegut, MD, MBA d , and Jerome J. Federspiel, MD, PhD c,e New Haven, CT
doi : 10.1016/j.ahj.2022.04.009
Volume 250, August 2022, Pages 11-22
To compare rates of severe maternal morbidity (SMM) for pregnant patients with a cardiac diagnosis classified by the modified World Health Organization (mWHO) classification to those without a cardiac diagnosis.
The effect of empagliflozin on contractile reserve in heart failure: Prespecified sub-study of a randomized, double-blind, and placebo-controlled trial
Jesper Jensen, MD, PhD a,b , Massar Omar, MD, PhD c,d,e , Mulham Ali, MD c,e , Peter H. Frederiksen, MD c,e , Caroline Kistorp, MD, PhD f,b , Christian Tuxen, MD, PhD g , Camilla F. Andersen, MD a , Julie H. Larsen, MD c , Mads Kristian Ersbøll, MD, PhD h , Lars Køber, MD, DmSc h,b , Finn Gustafsson, MD, DmSc h,b , Jens Faber, MD, DmSc i,b , Julie Lyng Forman, MSc, PhD j , Jacob Eifer Møller, MD, DmSc c,e,h,e , and Morten Schou, MD, PhD a,b Herlev, Denmark; Copenhagen, Denmark; Odense, Denmark
doi : 10.1016/j.ahj.2022.04.008
Volume 250, August 2022, Pages 57-65
Prognosis of elderly non-valvular atrial fibrillation patients stratified by B-type natriuretic peptide: ELDERCARE-AF subanalysis
Osamu Okazaki, MD, PhD a , Yorihiko Higashino, MD b , Koichi Yokoya, MD, PhD c , Yoshimori An, MD, PhD d , Kimihiko Tanizawa, PhD e , Yuki Imamura, MS e , Takuya Hayashi, MS f , Masaharu Akao, MD, PhD d , Ken Okumura, MD, PhD g , and Takeshi Yamashita, MD, PhD h Tokyo, Japan; Hyogo, Japan; Aichi, Japan; Kyoto, Japan; Kumamoto, Japan
doi : 10.1016/j.ahj.2022.05.009
Volume 250, August 2022, Pages 66-75
Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach
Lauren Gilstrap, MD a,b,c,# , Ronnie J. Zipkin, PhD c,d,# , Jonathan Aaron Barnes, MD a , Ashleigh King, MPH b , Alistair James O’Malley, PhD b,d , Thomas A. Gaziano, MD, MSc e,f , and Anna N.A. Tosteson, ScD b Lebanon, NH
doi : 10.1016/j.ahj.2022.04.007
Volume 250, August 2022, Pages 23-28
In clinical trials, sacubitril/valsartan has demonstrated significant survival benefits compared to angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACEi/ARB). Whether older patients with heart failure with reduced ejection fraction (HFrEF) benefit as much, due to higher rates of comorbidities, frailty and drug discontinuation, is unknown.
Genome-first recall of healthy individuals by polygenic risk score reveals differences in coronary artery calcium
Iain S. Forrest, BS a,b,c,d , Lili Chan, MD a,c,e , Kumardeep Chaudhary, PhD a,c,d,f , Aparna Saha, MD a,c , Huei Hsun Wen, MD a,c , Cristina Liriano Cepin, MPH a,c , Carla Marquez-Luna, PhD a,d , Ghislain Rocheleau, PhD a,d , Judy Cho, MD a,c,d,e , Jagat Narula, MD g , Girish N. Nadkarni, MD a,c,e,h,#,∗, and Ron Do, PhD a,c,d,#,∗∗ New York, NY
doi : 10.1016/j.ahj.2022.04.006
Volume 250, August 2022, Pages 29-33
Genetic risk for coronary artery disease (CAD) is commonly measured with polygenic risk scores (PRS); yet, the relationship of atherosclerotic burden with PRS in healthy individuals not at high clinical risk for CAD (ie, without a high pooled cohort equations [PCE] score) is unknown.
